Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)

About this funding opportunity

Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

Topic areas: Education and Training, Life Sciences and Health, Advanced Manufacturing and Industry.

Funding amount

This grant provides Varies in funding.

Deadline

Applications are due Jan 07, 2028. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• NGOs
• University
• SME
• Public Authorities
• Large Company
• Other

Eligibility

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs); U.S. Territory or Possession.

Agency

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional) is administered by National Institutes of Health (NIH), listed via Grants.gov.